Chinese(GB)     
Contact CFDA
   
HOME ABOUT CFDA WHAT'S NEW LAWS & REGULATIONS REGULATORY GUIDE DATA SEARCH SITE MAP
  Search      
Home >> Regulatory Guide  
Drugs
Examination and approval for import (incl. from Hong Kong, Macao and Taiwan) of packaging materials and containers in direct contact with drugs
2013-12-06

I. Project name: Examination and approval for packaging materials and containers in direct contact with drugs

II. Content of licensing: Approval of import (incl. from Hong Kong, Macao and Taiwan) of packaging materials and containers in direct contact with drugs
Product catalog of packaging materials and containers (referred to as "PMC") in direct contact with drugs under registration management
(I) Infusion bottles (bags, film and accessories);
(II) Ampoule
(III) Medicinal (injection, oral or topical dosage form) bottles (tube, cap);
(IV) Medicinal stopper;
(V) Medicinal prefilled syringes;
(VI) Medicinal eye (nose, ears) drops bottle (tube);
(VII)Medicinal rigid plate (film);
(VIII) Medicinal aluminum foil;
(IX) Medicinal ointment tube (box);
(X) Medicinal spray (gas) aerosol pump (valves, tanks, cylinders);
(XI) Medicinal desiccant.

III. Legal basis: "Drug Administration Law," " Regulations for Implementation of Drug Administration Law", " Regulations for Management of Packaging Materials and Containers in Direct Contact with Drugs"

IV. Charges: No charge

V. Quantity restrictions: No quantity limit for the licensing

VI. List of application dossiers:
"Registration Application Form for Packaging Materials and Containers of Imported Drugs ":
Information Number (1) Manufacturer’ legal production qualification documents, notarized documents and their Chinese translations;
Information No (2) Overseas Pharmaceutical Manufacturers’ entrustment of Chinese agents for application shall provide entrustment documents, notarized documents and Chinese translations. Chinese agents’ Business License or "Registration Certificate of Foreign Enterprises Permanent Representative in China " of Overseas Pharmaceutical Manufacturers’ Chinese Permanent Representatives;
Information No (3) Review of applied products’ overseas production, sales and application, and special reasons for registration application in China;
Information No (4) Quality inspection report of three batches of applied product issued by drug packaging inspection agency set or determined by CFDA;
Information No (5) Clean room (area) cleanliness inspection reports and self-test report of three batches of products;
Information No (6) Formulations of applied product;
Information No (7) Elaborations of applied products’ production process and main production and testing equipments;
Information No (8) Quality standards of applied products;
Information No (9) Research data of stability testing (drug compatibility test) of applied packaging materials jointly with drugs contained;
Information No (10) Floor plan of production plant and clean room (area) of applied products.
Specific requirements for the above application dossiers are detailed in Annex III of "Regulations for the management of packaging materials and containers in direct contact with drugs"

VII. Requirements for application dossiers:
(I) General requirements for application dossiers:
1. The first page of the application dossiers should be a project directory in which the application items shall be arranged in the order specified in Annex III of the "Regulations for the management of packaging materials and containers in direct contact with drugs" (CFDA Order No. 13). Each data shall indicate on the cover: PMC names, data item number, item name, applicant’s contact name, phone, address.
2. The Dossier should use A4 paper to print or copy, the contents should be clear and not to be altered. The Information should be complete and standardized, the data truthful and reliable.
3. The dossiers should be enclosed in sets into a Portfolio, whose envelope shall be marked with: Application classification, registration category, PMC name, X set/ Xth bags/ X in total, original/copy, the contact person, telephone, and name of the agency for registration application.
4. Submit two sets of complete application dossiers (1set of originals, one set of copies), 3 copies of the application forms (2 in the originals, 1 in the copies).
5. "PMC Registration Application Form": Download from CFDA website (www.cfda.gov.cn) The "Application Form for Developing the Offer Program ", fill in as required for print and filing.
6. Along with the submission or mail of the application dossiers, their electronic version shall be sent to the following Administrative Center by e-mail. e-mail address: slzx@cfda.gov.cn.
7. The data verification code of the electronic application forms should be consistent with paper application forms.
8. All application materials should be in Chinese accompanied by English translations, or other languages for reference. Chinese translation should be consistent with the original content.

(II) Specific requirements for application dossiers:
1. "PMC Registration Application Form": should be filled according to the explanatory notes, with signatures or seals (if any) of all the applicants.
2. Proof documents:
(1) Manufacturer’ legal production qualification documents, notarized documents and their Chinese translations
The applicant shall submit copies of the proof documents issued by the government departments of country of origin to approve its engagement in the production and distribution of drug PMC (similar to Chinese Business License, Production License or Registration Certificate, etc.), the original copy of notarized documents issued by public notary office and their Chinese translation. If the above-mentioned special approval documents are not required by the government of the country of origin, such information need not to be submitted after explanation of related information.
(2) Originals of the entrustment documents from overseas manufacturers to Chinese agencies for registration application, originals and Chinese translations of notarized documents issued by public notary offices of the country of origin
(3) Copies of Chinese domestic agency’s "Business License" or "Registration Certificate of Foreign Enterprises’ Permanent representative office in China"
3. Review of applied products’ overseas production, sales and application, and special reasons for registration application in China.
4. Test reports:
(1) Original copy of quality inspection report of three batches of the applied product issued by drug PMC inspection agencies set or determined by CFDA, that may be submitted separately after the technical review process.
(2) Original of Clean room (area) cleanliness inspection reports within one year of the application date shall be submitted.
(3) the self-test report of three batches of the applied products shall be submitted
5. Quality standards:
If the quality standards of drug PMC are new standards or corporate standards, the instructions for the drafting of standards should be provided
6. Other information shall be filed in accordance with Annex III of the "Provisions for the management of packaging materials and containers in direct contact with drugs" (CFDA Order No.13).

VIII. Diagram of application procedures:

IX. Licensing procedures:
(I) Acceptance:
After the Application is made to the Administrative Service Center, and the application dossiers submitted in order listed in Article VI of this "TIPS", the work staff shall review the format. If the application items are not subject to administrative examination and approval according to law, the decision of non-acceptance shall be immediately made. If the application items are not within the purview of the executive authorities, the decision of non-acceptance shall be immediately made and the applicant shall be informed to apply to related administrative institutions; .If the application dossiers have errors that can be corrected on the spot, the applicant shall be allowed to correct on the sport; if the application dossiers are incomplete or do not meet the statutory form, the applicant should be informed in full to enrich or rectify the relevant contents on the spot or within five days. If they are not informed, the application dossiers shall be deemed accepted from date of receipt. If the application dossiers are within the scope of the administrative institutions, the application materials are complete and comply with the statutory form, or the applicant has submitted all application materials in accordance with the requirements of the administrative authorities for enrichment or correction, the application shall be accepted for administrative examination and approval.


(II) PMC Registration inspection:
The applicants shall submit three consecutive batches of samples to drug PMC inspection agencies set or determined by CFDA. Drug PMC inspection agency shall perform test within 60 days after receiving the registration notice and samples, issue test report and submit to CFDA. CFDA shall conduct on-site inspection of the development of imported drug PMC and production conditions, and take samples.


(III) Technical review:
CFDA shall organize and complete the technical review within 90 days after receiving the test report and opinions, if additional information is needed, CFDA shall issue a notice for supplementary information to inform in full the applicant of the required supplementary information. The applicants shall complete once for all the required information within four months, if they failed to do so, the application for review shall be rejected.


(IV) Administrative licensing decision:
CFDA shall complete the examination and approval within 20 days after completion of the technical review. If a decision cannot be made within 20 days, an extension of 10 days may be granted upon approval of competent CFDA leaders. "Registration Certificate for Import of Drug PMC" shall be issued upon compliance; if the requirements are not met, a "Notice of approval opinion" shall be issued.


(V) Delivery:
Within 10 days from the date of decision making of administrative examination and approval, CFDA Administrative Service Center shall deliver the decision to the applicants.


(VI ) Re-review:
If the applicants disagree with the decision of disapproval, they can apply to CFDA for reconsideration within 10days upon receipt of the disapproval decision. The contents of the reconsideration shall be limited to the original application items and the original dossiers and samples submitted.
After receiving the application for reconsideration, CFDA shall make the decision for re-review within 50 days. If the original disapproval decision is canceled after re-review, the appropriate Drug PMC approval documents shall be issued; if the original decision is maintained, repeated application for reconsideration shall not be accepted by CFDA.

X. Commitment time frame:
Administrative licensing decision shall be made within 170 days from the date of acceptance. (Note: CFDA shall complete the examination and approval within 20 days after completion of the technical review, if not, an extension of 10 days can be granted upon approval of competent CFDA leaders; application for an extension above 10 days shall be submitted to the State Council for approval.)
The above timeframe does not include the time for supplementary information and the corresponding review.

XI. License validity and renewal:
"Registration Certificate for Import of Drug PMC" is valid for five years. If the import is still necessary upon expiry of the Registration Certificate, the applicant shall apply for renewal six months before the expiry.

XII. Annual inspection or annual review of the license: None

XIII. Authority of implementation:
Authority of implementation: CFDA
Location for acceptance: CFDA Administrative Service Center

XIV. Institutions for inquiries and complaints:
Inquiries: CFDA
Complaints: CFDA Bureau of Investigation and Enforcement, Department of Legal affairs
Note: The time frame of this TIPS counts on working days, excluding legal holidays

HOME | ABOUT CFDA | WHAT'S NEW | LAWS AND REGULATIONS | REGULATORY GUIDE | DATA SEARCH
| SITE MAP |
© CFDA
Constructed and Maintained by the Information Center of CFDA